Related Experiment Video

Updated: Aug 24, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Aromatase inhibitors in breast cancer

P E Lønning1

  • 1Section of Oncology, Institute of Medicine, Haukeland University Hospital, University of Bergen, 5021 Bergen, Norway. per.lonning@helse-bergen.no

Endocrine-Related Cancer
|May 28, 2004
PubMed

Insights

Third-generation aromatase inhibitors show superior efficacy in breast cancer therapy compared to earlier drugs. Endocrine evaluation serves as a reliable predictor of clinical outcomes, advancing breast cancer treatment and prevention strategies.

Area of Science:

  • Oncology
  • Pharmacology
  • Endocrinology

Background:

  • Aromatase inhibitors are crucial in breast cancer therapy.
  • Translational research has driven the development of these inhibitors.
  • Understanding endocrine regulation is key to breast cancer treatment.

Purpose of the Study:

  • To evaluate the biochemical and clinical efficacy of different generations of aromatase inhibitors.
  • To establish endocrine evaluation as a surrogate marker for clinical efficacy.
  • To explore the role of aromatase inhibitors in adjuvant therapy and prevention.

Main Methods:

  • In vivo studies assessing plasma oestrogen levels.
  • In vivo aromatase inhibition assays.
  • Analysis of large phase III clinical studies.

Main Results:

  • Third-generation aromatase inhibitors (anastrozole, letrozole, exemestane) demonstrate superior biochemical efficacy over first and second-generation drugs.
  • Endocrine evaluation of plasma oestrogen levels consistently correlates with clinical efficacy.
  • Phase III studies confirm improved clinical outcomes with third-generation inhibitors.

Conclusions:

  • Third-generation aromatase inhibitors represent a significant advancement in breast cancer therapy.
  • Endocrine monitoring is a valid surrogate for predicting clinical response.
  • Aromatase inhibitors are vital for adjuvant therapy and hold potential for breast cancer prevention.
  • Further research into cross-resistance between steroidal and non-steroidal compounds is warranted.

More Related Videos

Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells11:06

Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells

Published on: May 20, 2015

X-ray Visualization of Intraductal Ethanol-based Ablative Infusion for Prevention of Breast Cancer in Rabbit Models08:16

X-ray Visualization of Intraductal Ethanol-based Ablative Infusion for Prevention of Breast Cancer in Rabbit Models

Published on: September 12, 2025

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...